Drug
Enfortumab Vedotin
Enfortumab Vedotin: highest development phase Phase 3, developed by Astellas, Natera, Seagen and others. 11 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Astellas, Natera, Seagen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Enfortumab vedotin NCT07566156 | Phase 3 | Urothelial Cancer |
| Enfortumab vedotin NCT04223856 | Phase 3 | Urothelial Cancer |
| Enfortumab Vedotin NCT06553885 | Phase 2 | Metastatic Colorectal Cancer |
| Enfortumab vedotin NCT03219333 | Phase 2 | Carcinoma, Transitional Cell |
| Enfortumab vedotin NCT07908979 | Phase 2 | Bladder Cancer |
| Enfortumab vedotin NCT06809140 | Phase 2 | Muscle Invasive Bladder Urothelial Carcinoma |
| Enfortumab vedotin NCT04995419 | Phase 2 | Metastatic Urothelial Cancer |
| enfortumab vedotin NCT04225117 | Phase 2 | Locally Advanced or Metastatic Malignant Solid Tumors |
| Enfortumab Vedotin NCT07475806 | Phase 2 | Muscle-invasive Bladder Cancer |
| Enfortumab vedotin NCT05014139 | Phase 1 | Urinary Bladder Neoplasms |
| Enfortumab vedotin NCT03070990 | Phase 1 | Metastatic Urothelial Cancer |
Latest
No recent events.
Follow Enfortumab Vedotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.